ALO-02 and Embeda

Discussion in 'Pfizer' started by Anonymous, Mar 30, 2015 at 6:07 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    The short answer is yes, and the problem is managed care coverage. The opioid market is heavily generic. Payers don't like reimbursing branded opioids when generics are available. Payers also don't want to pay a premium for abuse deterrence.
     

  2. Anonymous

    Anonymous Guest

    Another dumb Pfizer Pfuck. Deliver your lunch, kiss their asses, and do some reading.
     
  3. Anonymous

    Anonymous Guest

    Another bitter asshole with nothing with substance to say, so you spew your ignorant hatred when someone stumps your pathetic tiny brain.
     
  4. Anonymous

    Anonymous Guest

    Wrong, as you are about most of what you've said.
    Naltrexone/Trexan failed. You need to look beyond the company BS and do your own research, you ignorant smug asshole
     
  5. Anonymous

    Anonymous Guest

    How much Embeda have we sold since it was relaunched? Anyone know???
     
  6. Anonymous

    Anonymous Guest

    Just when I think this thread is dead, it comes to life.
     
  7. Anonymous

    Anonymous Guest

    Sounds like we're launching BS-02!!
     
  8. Anonymous

    Anonymous Guest

    Yes, this thread is dead, but so is Pfizer. After all, Pfizer spent 4 billion dollars for King and all it got was about $20 million in sales after Embeda and Levoxyl were reintroduced. How pathetic is that? Pfizer got bitch slapped by a company it thought was inferior but, in reality, was better than Pfizer.

    Then again, maybe it's not all of Pfizer, maybe it's just jerks like Alan Litwack and his buddies, Donevan and Malhotra.
     
  9. Anonymous

    Anonymous Guest

    This thread is not dead! Hope never dies - and neither does the reckoning!!!
     
  10. Anonymous

    Anonymous Guest

    Don't forget that blockbuster Flector Patch!
     
  11. Anonymous

    Anonymous Guest

    Yes, combining the sales of Embeda, Flector, Levoxyl, Altace, Cytomel, Epipen, Synercid, Skelaxin (minus the $73 million dollar settlement), and Bacitracin ointment, which is as old as dirt, Pfizer must be netting a cool $200 million a year on the King acquisition. Not bad for for a $3.6 billion deal to become a kingpin in the opioid abuse deterrent market. It should only take about 20 years to break even. After that, it's pure gold!!!
     
  12. Anonymous

    Anonymous Guest

    Awww, would you legacy King people stop rubbing the King acquisition in our corporate faces? We know we f'cked up. We know we screwed you in the process. We didn't care then, but now we do, we really do. Cause we're Pfizer blue, and we care about youuuuu!
     
  13. Anonymous

    Anonymous Guest

    Donevan, speak to us Donevan!
     
  14. Anonymous

    Anonymous Guest

    Did anyone in Pfizer loose their job for that decision (other than the DMs and reps who got let go). A financial blunder like that deserves a pink slip!
     
  15. Anonymous

    Anonymous Guest

     
  16. Purdue Rep

    Purdue Rep Guest

    Purdue Rep here. Bored And reading to see what you Reps are saying about embeda. First, this product is a bust, and always will be. Not because it's a bad product, but bc of many issues: the obvious is poor managed care, docs don't make decisions; the market is declining; no need for embeda ABDF, bc docs don't care about it (tho they ACTA like they do) simple as this...patients are switched from morphine, bc of side effects (period)...why go from morphine to morphine???; did I mention docs DONT REALLY GIVE A SHIT ABOUT ABDF; (no offense here, but Pfizer reps aren't experts in pain mgt (Purdue is..period...why you ask? Because it's ALL our company has ever focused on); pain mgt is one of the hardest disease/disorders to sell (risk/benefits, etc..); patients make the decisions and docs can't and or won't stand up to their patients; products which potentially cause patients to go into withdrawal-scare doctors because it's another issue to deal with; docs (unless specialist's (and some of these are debatable) don't have a fucking clue how to adequately treat pain (most med schools only have 2 days training in pain mgt (and that's if it is a good program, sadly); docs don't trust pain reps, unless they "need support materials, etc.. on pain mgt..and in that case, they will ONLY reach out to Purdue reps, period) (again not trying to offend, just stating facts).. God I could go on and on. OxyContin branded will ONLY get squashed when our patent expires (which is very soon); we have never had any competition, nor will we; other ER oxycodone products will never perform much better than embeda (unless they find another pathway other than the MU receptors); why do I know this.. Look at embeda sales (no need to have another morphine product); OxyContin has NEVER had any competition, aside from IR oxycodone; when OxyContin goes generic, there will be a generic ER oxycodone (which exits now, but in limited quantities which Purdue controls at this point; (did you guys even know any of this?) If not, it's another form of proof that Pfizer isn't, nor ever will be, experts in training your reps to understand pain mgt and how to promote in this arena (again, not trying to offend..just stating facts). As for Hysingla (great product, but a few issues such as poor managed care, once a day dosing (patients do NOT want that at all); Zohydro is NEVER perform well, because the company and the FDA fucked up by approving and launching an ERO without ABDF. Docs will never feel comfortable RX it (except for their speakers, and I doubt even they will crank it out). Just trying to help you pours guys/gals understand your realities. Trust me, embeda will never ever squash OxyContin, because it works great and has better tolerability, along with the fact that docs feel it is slightly more potent) hell most of them don't realize that oxymorphinr and hydromorphine are more potent (dumbass druggies didn't/don't either); Trust me, I've been in this market a long time and these are the sad facts. Here it is a nutshell, OxyContin is the most loved and hated on the market...nothing will ever create multi billion dollars as it has done. Oh and Purdue is a debt free company. Here's a positive tip for you guys.. We now have a fired CEOS from Merk, so I'm sure our company is fucked! Happy selling, batches! Oh and happy 4th of July!
     
  17. Purdue rep

    Purdue rep Guest

    Sorry about the typosin my prior message, but I'm sure you get my points.
     
  18. Anonymous

    Anonymous Guest

    Lighten up Purdue rep. Pfizer has invested a total of $3.00 to launch Embeda. It doesn't care how well it does. If it does well, Pfizer makes a profit, if not, it spent $3 to give it a try.

    Embeda would take off if we bribed the pain docs like Purdue does by making all of them speakers. Pfizer is not putting anything but minor efforts into speaking engagements and signing up speakers, so you can chill out. End of discussion.

    As for your points about ABDF, I reluctantly agree. These docs who cry about liability are crying wolf. They are full of shit. They prescribe C2s solely to keep patients on the books hoping they can give them shots one day, which is how the docs make money.

    Until they plaster a doc's pic all over the internet and the New York Times who was arrested for not Rxing an ABDF C2 and knew the patient was an abuser, but still Rxed IR or ER C2s, and the patient died shooting it up his arm, then and only then the docs might wake up and prescribe Embeda and Hysingla solely. That and only that is what it will take to make that change. Our browbeating them will barely sink in.
     
  19. Anonymous

    Anonymous Guest

    OK Purdue Rep. Obviously NYHQ doesn't know how to commercialize an opiate. How much would Purdue give us (Pfizer) for Embeda and AL-02? $50 million and we'll throw in Alan Litwack and Sean Donevan!
     
  20. Purdue Rep

    Purdue Rep Guest

    I completely agree with your latter comments, however I must correct you on Purdue having speakers for OxyContin. We simply do not have speaker programs for OxyContin. Purdue wouldn't even consider that can of whoop ass and I HIGHLY doubt any physician would remotely touch that one! We do have speaker programs for Butrans and Hysingla. Those are complete jokes! Trust me, we're so dam cheap, I'd almost guarantee you we pay them pretty shitty. I'm not sure who at corporate chose them, but most of them don't prescribe either product and I would barely call any of the specialists, except for possibly 5 of them (and I'm being VERY liberal on that number). LOL! You might think it's easy to promote OxyContin, but I assure you it's undoubtedly the hardest product in any market to promote. No other company has come close to the negative media coverage that product has. Reformulated or not, docs still fear that scrutiny. So you are out of touch with reality for even thinking we pay any doc off, which is exactly the reason you particularly will never be successful in promoting pain products. I for one was being considerate of my statements toward your product and reps, but like many are what gives reps a bad name...jealous, ignorant, with a false since of your worth. I'd let you ride with me any time you like and let you see the reality reps at Purdue face. Keep in mind, this company is self destructing with our new fearless leader.